Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC)

Authors :: Elena Castro
Samanta Salvi
Begoña Mellado
Cristian Lolli
Giuseppe Schepisi
Anna Wingate
David Olmos
Giorgia Gurioli
Ugo De Giorgi
Daniel Wetterskog
Nuria Romero-Laorden
Emanuela Scarpi
Mercedes Marin
Anuradha Jayaram
Umberto Basso
Gerhardt Attard
Ana Medina
Enrique Gonzalez-Billalabeitia
Vincenza Conteduca
Giuseppe Fornarini
Source :: Journal of Clinical Oncology. 36:5074-5074
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 5074Background: Plasma AR (pAR) gain identifies CRPC with worse outcome on abiraterone (abi) or enzalutamide (enza). We aimed to evaluate whether taxanes in CRPC are active regardless of AR status ...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
030232 urology & nephrology
Castration resistant
medicine.disease
Androgen receptor
03 medical and health sciences
Abiraterone
chemistry.chemical_compound
Prostate cancer
0302 clinical medicine
chemistry
030220 oncology & carcinogenesis
Internal medicine
medicine
Enzalutamide
business

Tools